Advances in the development of entry inhibitors for sialic-acid-targeting viruses (original) (raw)
Therapies for coronaviruses. Part I of II – viral entry inhibitors
Tommy R Tong
Expert Opinion on Therapeutic Patents, 2009
View PDFchevron_right
Sialic Acid Is a Cellular Receptor for Coxsackievirus A24 Variant, an Emerging Virus with Pandemic Potential
Niklas Arnberg
Journal of Virology, 2008
View PDFchevron_right
Structural basis for human coronavirus attachment to sialic acid receptors
Berend Jan Bosch
Nature Structural & Molecular Biology, 2019
View PDFchevron_right
A Review on the Novel Coronavirus Disease based on In-silico Analysis of Various Drugs and Target Proteins
Gauravi Trivedi
Journal of Pure and Applied Microbiology
View PDFchevron_right
Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases
Prof. Dr. Soleiman Mahjoub
2021
View PDFchevron_right
Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses
W. Spaan
Proceedings of the National Academy of Sciences, 1988
View PDFchevron_right
Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
Han Ju
Journal of Medicinal Chemistry, 2020
View PDFchevron_right
Sialic acid-Dependent Binding and Viral Entry of SARS-CoV-2
duong bui
2021
View PDFchevron_right
Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms
Stefan Sarafianos
View PDFchevron_right
Human coronaviruses OC43 and HKU1 bind to 9- O -acetylated sialic acids via a conserved receptor-binding site in spike protein domain A
Geert-jan Boons
Proceedings of the National Academy of Sciences, 2019
View PDFchevron_right
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Penelope Duerksen-hughes
Virology Journal
View PDFchevron_right
Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus
Hubert Laude
Journal of virology, 1997
View PDFchevron_right
Targeting Virus-Host Interaction: An in Silico Approach to Develop Promising Inhibitors Against COVID-19
Aroni Chatterjee
View PDFchevron_right
Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions
Albert Aniagyei
Journal of Applied Pharmaceutical Science, 2021
View PDFchevron_right
Strategies and Challenges to Develop Therapeutic Candidates against COVID-19 Pandemic
Rohit Bhatia
The Open Virology Journal
View PDFchevron_right
Credible Protein Targets and Curative Strategies for COVID-19: a Review
neelu singh
SN Comprehensive Clinical Medicine
View PDFchevron_right
The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
Dr. Rahul Pawara
Topics in Current Chemistry, 2021
View PDFchevron_right
Clinical Evidence of Possible Drug Targets and Pharmacological Management of Novel Covid-19: The World Threatening Virus
Science World Publishing
Advanced Clinical Pharmacology and Toxicology, Therapeutics, 2020
View PDFchevron_right
Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
Stalin Raj
Proceedings of the National Academy of Sciences, 2017
View PDFchevron_right
Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants
Kabita Pandey
Journal of Virology
View PDFchevron_right
HTCC: Broad Range Inhibitor of Coronavirus Entry
Krzysztof Pyrc
PLOS ONE, 2016
View PDFchevron_right
Evaluation of the Cytotoxic and Antiviral Effects of Small Molecules Selected by In Silico Studies as Inhibitors of SARS-CoV-2 Cell Entry
Cristina P R Xavier
Molecules
View PDFchevron_right
Coronavirus - Drug Discovery and Therapeutic Options
Zaid Tayyab
Journal of Pharmaceutical Research International, 2021
View PDFchevron_right
COVID-19: Search for Therapeutics
Neelam Holkar
Integrative Molecular Medicine
View PDFchevron_right
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
Mohammad Alkhatib
Drug Resistance Updates, 2020
View PDFchevron_right
Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19
Gayathri Gopal
Journal of Medical Virology, 2021
View PDFchevron_right
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Philip Tzou
Viruses
View PDFchevron_right
Combinatorial therapeutic plan for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters
Nabanita Roy Chattopadhyay
2020
View PDFchevron_right
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors
Vijay Nuthakki
PLOS Pathogens, 2021
View PDFchevron_right